Zandian Arash, Forsström Björn, Häggmark-Månberg Anna, Schwenk Jochen M, Uhlén Mathias, Nilsson Peter, Ayoglu Burcu
Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH - Royal Institute of Technology , SE-171 21 Solna, Sweden.
J Proteome Res. 2017 Mar 3;16(3):1300-1314. doi: 10.1021/acs.jproteome.6b00916. Epub 2017 Feb 9.
The underlying molecular mechanisms of autoimmune diseases are poorly understood. To unravel the autoimmune processes across diseases, comprehensive and unbiased analyses of proteins targets recognized by the adaptive immune system are needed. Here we present an approach starting from high-density peptide arrays to characterize autoantibody repertoires and to identify new autoantigens. A set of ten plasma and serum samples from subjects with multiple sclerosis, narcolepsy, and without any disease diagnosis were profiled on a peptide array representing the whole proteome, hosting 2.2 million 12-mer peptides with a six amino acid lateral shift. On the basis of the IgG reactivities found on these whole-proteome peptide microarrays, a set of 23 samples was then studied on a targeted array with 174 000 12-mer peptides of single amino acid lateral shift. Finally, verification of IgG reactivities was conducted with a larger sample set (n = 448) using the bead-based peptide microarrays. The presented workflow employed three different peptide microarray formats to discover and resolve the epitopes of human autoantibodies and revealed two potentially new autoantigens: MAP3K7 in multiple sclerosis and NRXN1 in narcolepsy. The presented strategy provides insights into antibody repertoire reactivity at a peptide level and may accelerate the discovery and validation of autoantigens in human diseases.
自身免疫性疾病的潜在分子机制尚不清楚。为了揭示各种疾病中的自身免疫过程,需要对适应性免疫系统识别的蛋白质靶点进行全面且无偏差的分析。在此,我们提出一种从高密度肽阵列开始的方法,以表征自身抗体库并鉴定新的自身抗原。在一个代表整个蛋白质组的肽阵列上,对来自患有多发性硬化症、发作性睡病以及未进行任何疾病诊断的受试者的十份血浆和血清样本进行了分析,该阵列包含220万个12肽,氨基酸侧移为六个。基于在这些全蛋白质组肽微阵列上发现的IgG反应性,随后在一个靶向阵列上对23个样本进行了研究,该靶向阵列包含17.4万个单氨基酸侧移的12肽。最后,使用基于珠子的肽微阵列,对更大的样本集(n = 448)进行了IgG反应性验证。所提出的工作流程采用了三种不同的肽微阵列形式来发现和解析人类自身抗体的表位,并揭示了两种潜在的新自身抗原:多发性硬化症中的MAP3K7和发作性睡病中的NRXN1。所提出的策略在肽水平上提供了对抗体库反应性的见解,并可能加速人类疾病中自身抗原的发现和验证。